Sphingosine kinase 1 (SPHK1) is overexpressed in solid tumors and leukemia. However, the mechanism of SPHK1 overexpression by oncogenes has not been defined. We found that v-Src-transformed NIH3T3 cells showed a high SPHK1 mRNA, SPHK1 protein and SPHK enzyme activity. siRNA of SPHK1 inhibited the growth of v-Src-NIH3T3, suggesting the involvement of SPHK1 in v-Src-induced oncogenesis. v-Src-NIH3T3 showed activations of protein kinase C-a, signal transducers and activators of transcription 3 and c-Jun NH 2 -terminal kinase. Their inhibition suppressed SPHK1 expression in v-Src-NIH3T3, whereas their overexpression increased SPHK1 mRNA in NIH3T3. Unexpectedly, the nuclear run-on assay and the promoter analysis using 5 0 -promoter region of mouse SPHK1 did not show any significant difference between mock-and v-Src-NIH3T3. Furthermore, the half-life of SPHK1 mRNA in mock-NIH3T3 was nearly 15 min, whereas that of v-Src-NIH3T3 was much longer. Examination of two AU-rich region-binding proteins, AUF1 and HuR, that regulate mRNA decay reciprocally, showed decreased total AUF1 protein associated with increased tyrosine-phosphorylated form and increased serine-phosphorylated HuR protein in v-Src-NIH3T3. Modulation of AUF1 and HuR by their overexpression or siRNA revealed that SPHK1 mRNA in v-Src-and mock-NIH3T3 was regulated reciprocally by these factors. Our results showed, for the first time, a novel mechanism of v-Src-induced SPHK1 overexpression.
Introduction
Sphingosine kinase (SPHK) is a key enzyme in the sphingolipid metabolic pathway as it forms an essential checkpoint that regulates the relative levels of sphingosine 1-phosphate (S1P), sphingosine and ceramide. SPHK mediates the growth response by several growth stimulation signals (Taha et al., 2006) . S1P is a bioactive sphingolipid metabolite that is produced by SPHK, and has been implicated in many biological processes such as cell survival, cell proliferation, angiogenesis and cell migration. S1P can function intracellularly as a second messenger or activate signaling through S1P receptors in an autocrine and/or paracrine fashion (Alvarez et al., 2007) .
We previously reported that SPHK1 mRNA was stimulated with nerve growth factor (NGF) or phorbol ester (Nakade et al., 2003; Sobue et al., 2005) . Furthermore, SPHK1 overexpression enhances the growth of cells even without extracellular stimulation (Olivera et al., 1999) . These results suggest an oncogenic role of SPHK1 in cancer. Kawamori et al. (2006) reported that SPHK1 mRNA and protein levels were increased in human colon cancer, and we recently observed an increased SPHK1 mRNA in acute leukemia and myelodysplastic syndromes (Sobue et al., 2006 ). An inhibitor of SPHK is antiproliferative and proapoptotic to several tumor cell lines (French et al., 2003) . We as well as others have shown that the inhibition of SPHK1 activity enhances the chemosensitivity of cancer cells (Bektas et al., 2005; Akao et al., 2006; Bonhoure et al., 2006) .
However, direct analyses of the relationship between oncogene and SPHK1 expression are rare. Xia et al. (2000) reported mutated Ras as a stimulator of SPHK, but its underlying mechanism has not been extensively studied. Src and Src-family protein kinases (SFKs) are proto-oncogenes that play key roles in cell morphology, motility, proliferation and survival. v-Src is encoded by the chicken oncogene of Rous sarcoma virus, and c-Src, encoded by a physiological gene, is the first example of the proto-oncogenes. Activation of SFKs allows phosphorylation of specific substrates. Growth stimulation by v-Src requires activation of MEK/ERK (mitogenactivated protein kinase kinase/extracellular regulated kinase) and other signaling pathways (Frame, 2004) .
v-Src, but not c-Src, transforms NIH3T3 cells. However, like v-Src, activated mutants of c-Src can transform cells in culture and induce tumors in chickens. Recently, overexpression of c-Src was observed in many human tumors (Dehm et al., 2001; Dehm and Bonham, 2004) . Transformation due to v-Src probably results from perturbation of normal growth or a developmental regulatory pathway mediated by c-Src. Analysis of the mechanism of SPHK1 overexpression by oncogenes is important to evaluate their clinical significance because SPHK inhibitors could be expected to show promise as valuable reagents to treat solid tumors and leukemia.
In this study, we analysed SPHK expression using v-Src-transformed NIH3T3 cells and found a novel mechanism of SPHK1 mRNA increase based on its stabilization. We further examined the involvement of AU-rich region (AUR)-binding proteins (AUBPs), AUF1 and HuR (Kloss et al., 2004; Lal et al., 2004; Raineri et al., 2004) , regulating mRNA decay in the opposite direction. The role of the aberrant expression of AUBPs in v-Src-NIH3T3 in SPHK1 mRNA stabilization and the signaling pathway, which starts from v-Src and ends at the binding of AUBPs to 3 0 UTR of SPHK1 mRNA, were discussed.
Results
v-Src-transfected cells showed both increased SPHK1 mRNA and enzyme activity SPHK1 protein levels of stable transfectants of mock-, dominant-negative (DN) c-Src-, v-Src-and mutated H-Ras-NIH3T3 are shown in Figure 1a . Overexpression of Src or Ras of respective transformants was also confirmed. DN-c-Src-NIH3T3 also showed an increase of Src protein. Although Xia et al. (2000) reported the increased SPHK enzyme activity in mutated H-Rastransfected NIH3T3 cells, our repeated trial of mutated H-Ras transfection into NIH3T3 cells showed a marginal SPHK1 protein overexpression and enzyme activity, although high SPHK1 protein levels were constantly observed in v-Src-transformed NIH3T3. Transient transfection experiments of mutated K-Ras, mutated H-Ras and v-Src showed similar results (data not shown).
SPHK enzyme activity shown in Figure 1b also demonstrates its increase in v-Src-NIH3T3 and a mild increase in mutated H-Ras-NIH3T3. Figure 1c shows SPHK1 mRNA measured by real-time reverse transcriptase (RT)-PCR. Both v-Src and mutated H-Ras increased SPHK1 mRNA. The increase of SPHK1 mRNA in v-Src-NIH3T3 is also much higher than that of mutated H-Ras-NIH3T3. In addition, DN-c-Src-NIH3T3 showed a very low SPHK1 mRNA, suggesting that the Src pathway is important for SPHK1 transcription. On the basis of these results, we focused on the mechanism of increased SPHK1 mRNA by v-Src.
siRNA of SPHK1 inhibited cell proliferation of v-Src-transformed NIH3T3 v-Src-NIH3T3 showed higher cell proliferation on day 4 (Figure 2a ) as well as anchorage-independent growth (data not shown) compared to mock-NIH3T3. Enhanced cell proliferation of v-Src-NIH3T3 was significantly inhibited by siRNA of SPHK1 but not by scramble siRNA (Figure 2b ). However, these effects Figure 1 (a) Sphingosine kinase 1 (SPHK1) protein level. Stable transfectants of control expression vector (pcDNA3.1), dominantnegative (DN) c-Src, v-Src and mutated H-Ras expression vectors were analysed for SPHK1 expression. Expression of Src or Ras was also confirmed using anti-Src and anti-Ras antibody, respectively. b-Actin was used as the internal control. Anti-p-Src antibody detects phosphorylated (activated) Src protein. (b) SPHK enzyme activity of each transfectant described in Figure 1a was measured in triplicate as described in 'Materials and methods'. (c) SPHK1 mRNA level. SPHK1 mRNA was measured by quantitative reverse transcriptase (RT)-PCR method as described in 'Materials and methods'. mRNA level was expressed as SPHK1/b-actin, and the relative ratio of mock-NIH3T3 was regarded as 1.0. Assay was done in triplicate and results described were the mean from three different experiments.
v-Src-induced SPHK1 mRNA accumulation S Sobue et al were less remarkable in mock-NIH3T3 (data not shown). Inhibition of SPHK1 protein expression by siRNA for SPHK1 is shown in Figure 2c .
Effect of inhibitors of signal transduction on SPHK1 protein expression
Previous reports have shown that many signaling proteins are involved in v-Src-induced NIH3T3 transformation, including ERK, c-Jun NH 2 -terminal kinase 1 (JNK1) and signal transducers and activators of transcription 3 (Stat3; Greulich et al., 1996; Stofega et al., 1997; Turkson et al., 1999) . Our v-Src-NIH3T3 also showed the activation of protein kinase C-a (PKCa), Stat3 and JNK, but not PKCd, ERK, p38 mitogen-activated protein kinase or AKT activation ( Figure 3a and data not shown). The effect of various inhibitors of these signaling components on the SPHK1 protein expression of v-Src-NIH3T3 was examined ( Figure 3b) . A pan-PKC (p-PKC) inhibitor, calphostin C, and a PKCa inhibitor, Go6976, inhibited SPHK1 protein expression in v-Src-NIH3T3. A JNK1 inhibitor (SP600125) and a cell-permeable Stat3 inhibitor also inhibited the SPHK1 protein level.
Promoter analysis and nuclear run-on assay On the basis of our previous reports, increased SPHK1 mRNA is considered to be due to its enhanced transcription (Nakade et al., 2003; Sobue et al., 2005) . Figure 3c shows the promoter analysis of mouse SPHK1a gene. The promoter region covering À791 to À4 bp of 5 0 of SPHK1a showed no significant change in the promoter activity between v-Src-NIH3T3 and mock-NIH3T3. Figure 3d shows the nuclear run-on analysis of mock-NIH3T3 and v-Src-NIH3T3. A newly synthesized SPHK1 mRNA was also not significantly changed, which supports the promoter analysis. On the contrary, the treatment of NIH3T3 cells with a phorbol ester, phorbol 13-myristate 12-acetate (PMA), increased SPHK1 mRNA about 2.5-fold.
v-Src elongated SPHK1 mRNA half-life Unexpectedly, our analysis suggested the possibility that v-Src increased SPHK1 mRNA by mRNA stabilization. Figure 4a illustrates the mRNA half-life of SPHK1, indicating that in NIH3T3 it was very short, about 10-15 min, whereas it was remarkably elongated, approximately 100 min, in v-Src-NIIH3T3. Go6976 and calphostin C (Figure 4b ) significantly decreased SPHK1 mRNA half-life of v-Src-NIH3T3, suggesting the positive role of PKCa on SPHK1 mRNA stabilization in v-Src-NIH3T3. We examined SPHK1 mRNA by transiently transfecting PKCa, Stat3 and JNK1-expression vector into NIH3T3. Figure 4c shows that constitutively active PKCa, Stat3 and JNK1 increased SPHK1 mRNA, though the increased mRNA by Stat3 and JNK1 transfection was much less. On the basis of these results, we conclude that at least the PKC signaling pathway plays a role in the mRNA stabilization.
Effect of 3
0 -untranslated region of SPHK1 on its mRNA half-life It is known that the AU-rich element (ARE) in the 3 0 UTR is involved in mRNA decay (Meyer et al., 2004) . The luciferase assay has been used for examining the involvement of 3 0 UTR in mRNA half-life. Figure 4d illustrates the effect of 3 0 UTR on luciferase activity as the index of SPHK1 mRNA stability. The addition of full-length 3 0 UTR inhibited luciferase expression in mock-NIH3T3. However, the luciferase activity was relatively well maintained in v-Src-NIH3T3, suggesting that v-Src inhibited SPHK1 mRNA decay through this 3 0 UTR. Because 3 0 UTR of SPHK1 does not contain the consensus AUR, which is the hallmark of a mRNA decay signal, we divided this 3 0 UTR into two parts. The decrease in luciferase activity of the second but not the first half of 3 0 -UTR-luciferase vector was observed in mock-NIH3T3 (Figure 4d ). The examination of the 5 0 UTR of SPHK1 showed no positive results (data not shown).
Two AUBPs, AUF1 and HuR, in v-Src-NIH3T3 We next examined two AUBPs, AUF1 and HuR (Kloss et al., 2004; Lal et al., 2004; Raineri et al., 2004) . AUF1 is responsible for mRNA decay by binding to ARE and transferring the complex to the degradation v-Src-induced SPHK1 mRNA accumulation S Sobue et al system (Chen et al., 2001) . Most ELAV (embryonic lethal abnormal vision)/Hu proteins (HuA, HuB, HuC and HuD) are present in neuronal tissue, whereas HuR protein is ubiquitously expressed and stabilizes mRNA decay by binding to ARE (Good, 1992) .
Interestingly, a considerable decrease of AUF1 but not HuR protein was observed in v-Src-NIH3T3 as compared to mock-NIH3T3 (Figure 5a ). In addition, increased tyrosine-phosphorylated AUF1 was observed in v-Src-NIH3T3. Furthermore, an increase in serinephosphorylated HuR was observed in v-Src-NIH3T3 either by immunoprecipitation with anti-HuR antibody followed by western blotting with an antiphosphoserine PKC substrate antibody, or by immunoprecipitation with an antiserine/threonine antibody followed by western blotting with an anti-HuR antibody ( Figure 5b ). siRNA of AUF1 greatly increased the SPHK1 mRNA of mock-NIH3T3, whereas siRNA of HuR inhibited the SPHK1 mRNA of v-Src-NIH3T3 ( Figure 5c ). Overexpression of AUF1 decreased SPHK1 mRNA of v-Src-NIH3T3 (Figure 5d , left). Transfection of constitutively active PKCa induced serine-phosphorylated HuR of mock-NIH3T3 and increased its SPHK1 mRNA level (Figure 5d , right; Figure 4c ).
RNA immunoprecipitation
In order to confirm that the binding of 3 0 UTR of SPHK1 and AUF1 as well as HuR proteins was v-Src-induced SPHK1 mRNA accumulation S Sobue et al involved in the mRNA decay, we performed an RNAchromatin immunoprecipitation assay (RNA-ChIP) described by Pan et al. (2005) . Both mock-NIH3T3 and v-Src-NIH3T3 were subjected to RNA immunoprecipitation as described in 'Materials and methods'. Figure 6a shows that AUF1 but not HuR was bound to 3 0 UTR of SPHK1 in mock-NIH3T3, whereas HuR but not AUF1 was bound to 3 0 UTR of SPHK1 in v-Src-NIH3T3. The binding of HuR to the 3 0 UTR of SPHK1 was inhibited by the p-PKC inhibitor, calphostin C, and the PKCa inhibitor, Go6976, but not the PKCd inhibitor, rottlerin (Figure 6b ). This suggests that the difference in the decay rate of SPHK1 observed in these two cells was mainly due to the binding of a different AUBP (or the relative ratio of these AUBPs) to the 3 0 UTR of SPHK1 mRNA. In order to confirm the binding of AUBPs and 3 0 UTR of SPHK1 further, we examined the binding of 3 0 UTR and AUBPs by a biotin-labeled RNA-pull-down assay. After collecting complexes of the biotinylated RNA and binding proteins by streptavidin-conjugated beads, binding proteins were identified by western blotting. Using the full-length 3 0 UTR, HuR binding was identified in v-Src-NIH3T3 but not in mock-NIH3T3 (Figure 6c, left) .
Probably because of the limited abundance of AUF1, we could not obtain the positive signal for AUF1 (data not shown). Among the eight biotin-labeled RNA fragments of 3 0 UTR of SPHK1, positive signals were observed in the fragments 7 and 8 located at the most 3 0 end of 3 0 UTR (Figures 6c, right) . Interestingly, a difference of band intensity between mock-and vSrc-NIH3T3 was observed in fragment 8, suggesting that more HuR was bound to this region in v-Src-NIH3T3, whereas in mock-NIH3T3, AUF1 binding to the same region was predominant.
Discussion
Recently, Xia et al. (2000) reported that mutated H-Ras increases SPHK enzyme activity. In our study, v-Src was found to increase SPHK enzyme activity, SPHK1 mRNA and SPHK1 protein expression in either transient or stable transfectants. We also established a stable DN-c-Src-NIH3T3 without an increase in SPHK enzyme activity, suggesting that enhanced SPHK1 expression is due to the intrinsic v-Src functions. 0 UTR on mRNA stability were examined using luciferase vectors with or without 3 0 -UTR insertion as described in 'Materials and methods'. Each luciferase vector was transfected into mock-NIH3T3 and v-Src-NIH3T3. After 24 h, luciferase activity was examined and was corrected with b-gal activity. Experiments were performed in triplicate and were repeated at least three times. Mean±s.d. is shown. Relative luciferase activity of vectors without 3 0 UTR was regarded as 100%. Vector: vector without 3 0 -UTR insert, full: full-length 3 0 -UTR insert; first: the first half of 3 0 -UTR insert; second: the second half of 3 0 -UTR insert.
v-Src-induced SPHK1 mRNA accumulation S Sobue et al
Western blotting with an antiphosphorylated Src antibody confirmed the activated status of Src in v-Src-NIH3T3 (Figure 1a) . The enhanced expression of SPHK1 by v-Src (Figure 1c) does not take place at the level of translation as reported in the case of a hypoxia-inducible factor (HIF)-1 (Karni et al., 2002) , but at the posttranscriptional level. The involvement of SPHK1 in the enhanced proliferation of v-Src-NIH3T3 compared to mock-NIH3T3 was demonstrated using siRNA for SPHK1 (Figure 2b) . The partial inhibition of cell growth of v-Src-NIH3T3 by siRNA for SPHK1 suggests that SPHK1 is not the sole factor in v-Src-induced transformation.
Analysis of the signal-transduction pathway of v-Src-NIH3T3 revealed that PKCa, JNK1 and Stat3, but not Stat5 (data not shown), were highly activated in v-Src-NIH3T3. These results were consistent with those of previous reports (Greulich et al., 1996; Stofega et al., 1997; Turkson et al., 1999) . Various inhibitors of PKCa, Stat3 and JNK revealed their positive involvement in SPHK1 expression (Figure 3b) . However, the interrelationship between these factors remains to be determined.
Stable and transient v-Src expression induces a number of gene products (Tezuka et al., 1996) . A v-Src-induced increase in target gene transcription was reportedly mediated by various cellular signaling pathways or transcription factors such as MEKK1/JNK and raf/MEK/ERK pathways (Xie and Herschman, 1995) or Sp1 and EGR-1 (Qureshi et al., 1991; Kuo et al., 2006) . In these studies, promoter analysis clearly showed that v-Src increased target gene transcription. However, our present analysis showed that the promoter activity revealed no significant difference between v-Src-NIH3T3 and mock-NIH3T3 (Figure 3c ). Moreover, the nuclear run-on assay (Figure 3d ) failed to show any significant increase in the transcription rate of SPHK1 in v-Src-NIH3T3 compared to mock-NIH3T3, whereas PMA increased de novo transcription about 2.5-fold. We have reported that the 5 0 -promoter region is mainly v-Src-induced SPHK1 mRNA accumulation S Sobue et al involved in SPHK1 transcription when activated by agonists including PMA, cytokines, NGF and glial cell line-derived neurotrophic factor (Nakade et al., 2003; Sobue et al., 2005; Murakami et al., 2007) . Thus, these results suggest that an increase of v-Src-and PMAinduced SPHK1 mRNA was mediated by different mechanisms. SPHK1 mRNA abundance is determined by the rates of transcription and mRNA decay. The elongation of SPHK1 mRNA half-life was observed in v-Src-NIH3T3 ( Figure 5 ). In cells transformed by v-Src, PKCa, Stat3 and JNK1 were overexpressed and activated (Borner et al., 1992) . The relationship between PKC and Stat3 was previously reported (Park et al., 2002 , Gartsbein et al., 2006 , suggesting that Stat3 is located downstream of PKC. The JNK pathway was involved in IL-2 mRNA stabilization (Chen et al., 1998) . Although transient transfection of these genes was shown to increase SPHK1 mRNA (Figure 4c ), further analysis is needed to elucidate how these components act in signaling by v-Src in the SPHK1 mRNA decay. Because PKCa expression induced the highest SPHK1 mRNA (Figure 4c) , we further examined the involvement of PKCa. The involvement of PKC in mRNA half-life elongation (Hanford and Glembotski, 1996; Shih et al., 1999) was reported previously.
A model of regulated mRNA decay has been proposed (Meyer et al., 2004) . Two types of proteins have been reported to be involved in this process; one is the mRNA decay-accelerating factors (AUF1 and TTP) and the other is an mRNA decay-inhibiting factor (HuR; Wilusz et al., 2001) , both of which bind to 3 0 UTR of mRNA. In our case, 3 0 UTR of SPHK1 has no AUUA or UUAUUUA sequence. However, the absence of typical ARE does not necessarily exclude the mRNA decay through 3 0 UTR. Very few among the stabilized genes in malignant T cells have the consensus AREs (Vlasova et al., 2005) although AUBP was not precisely analysed. Our reporter assay using a luciferase vector containing the 3 0 UTR of SPHK1 (Figure 4d ) was consistent with the elongation of mRNA half-life and also revealed that a decrease in luciferase activity due to 3 0 UTR was much less in v-Src-NIH3T3 than in mock-NIH3T3. Our results suggest that the inhibition of SPHK1 mRNA decay by a v-Srcmediated signaling pathway is involved in the growth advantage of v-Src-NIH3T3, and that the second part of 3 0 UTR is important in the mRNA decay. Recently, Bromann et al. (2005) reported that platelet-derived growth factor stimulates the c-Srcdependent mRNA stabilization of specific early genes. In v-Src-transformed chick embryofibroblasts, E3/pCEF4 mRNA was stabilized with its 3 0 UTR containing the AUUUA sequence (Stoeckle and Hanafusa, 1989; Blobel and Hanafusa, 1991) . Fawal et al. (2006) reported that nucleophosmin-anaplastic lymphoma kinase phosphorylates AUF1 and elongates the half-life of ARE-containing mRNAs. NPM/ALK was also reported to activate c-Src so as to mediate its mitogenicity (Cussac et al., 2004) . Therefore, it is likely that v-Src phosophorylates tyrosine residues of AUF1 and inhibits its mRNA decay activity.
In the current study, AUF1 protein expression in v-Src-NIH3T3 was greatly diminished whereas the tyrosine-phosphorylated form was increased and v-Srcphosphorylated HuR was increased in v-Src-NIH3T3 compared to mock-NIH3T3, although the total HuR protein levels were identical between the two (Figure 5a ). The decrease in total AUF1 protein and increased tyrosine-phosphorylated form of AUF1 as well as phosphorylated HuR might be effective in SPHK1 mRNA stabilization. HuR phosphorylation could also be detected by antiserine-phosphorylated PKC substrate antibody, suggesting PKC induced HuR phosphorylation in v-Src-NIH3T3. (1 mM) and rottlerin (2.5 mM) was examined in this assay using v-Src-NIH3T3 cells. (c) Biotinylated RNA-pull-down assay. Left: biotin-labeled full-length 3 0 UTR of sphingosine kinase 1 (SPHK1) mRNA (15 mg), prepared by in vitro transcription described in the Supplementary information, was incubated with 100 mg of mock-(M) or v-Src-NIH3T3 (S) cytoplasmic extract, and the complexes were collected by Dynabeads as described in the 'Materials and methods'. Protein components of the complexes were identified by western blotting using an anti-HuR antibody. In case of AUF1, the incubation of more cytoplasmic extract did not show any significant signal, probably due to the limited amount of AUF1 protein (data not shown). Right: eight biotin-labeled synthetic fragments of 3 0 UTR of SPHK1 mRNA (2 mg each) were incubated with the cytoplasmic extract (100 mg for AUF1 and 15 mg for HuR) of mock-(M) and v-Src-NIH3T3 (S), and the complexes were collected by Dynabeads as described in the 'Materials and methods'. Protein components of the complexes were identified by western blotting using either an anti-AUF1 or an anti-HuR antibody. The upper part illustrates each fragment, whose sequence is available in Supplementary information. Although the consensus AU-rich sequence was not present, a stretch of UUU was illustrated as UU as the candidate cis-element for the AU-rich region-binding protein (AUBP) binding. We have shown the signaling pathway extending from v-Src to PKCa activation and HuR phosphorylation, thereby leading to the binding of activated HuR to 3 0 UTR of SPHK1. Because PKC is a serine/threonine kinase, the upstream signaling of tyrosine phosphorylation of AUF1 might not be through PKC (Wilson et al., 2003) , and further experiments are needed. The involvement of AUF1 and HuR in SPHK1 mRNA halflife in v-Src-NIH3T3 was further supported by siRNA transfection and overexpression experiments (Figures 5c  and d) , indicating the unique and significant role of AUF1 and HuR. Furthermore, direct binding of AUF1 to 3 0 UTR of SPHK1 was detected in the RNA-ChIP assay and RNA-pull-down assay (Figures 6a-c and 7) , suggesting that AUF1 is involved in SPHK1 mRNA decay in mock-NIH3T3, and that HuR is implicated in SPHK1 mRNA stabilization in v-Src-NIH3T3 at least through the most 3 0 part of 3 0 UTR. A UUUU sequence in this fragment might be the candidate of cis-element in binding, however, further analysis is needed.
Taken together, the current study demonstrated, for the first time, that the SPHK1 mRNA half-life is relatively short in noncancerous cells and that its stabilization by PKC and probably other signaling pathways is involved in its increased expression. Effective growth inhibition by siRNA of SPHK1 of v-Src-NIH3T3, in which overexpression of SPHK1 was due to the accumulation of its mRNA, suggests the possible application of SPHK inhibitors or siRNA as a strategy of novel cancer treatment.
Materials and methods

Cell lines and reagents
Stable v-Src transformants of NIH3T3 cells were prepared by transfecting pcDNA3.1-(Invitrogen, Carlsbad, CA, USA) containing v-Src, which was a gift from Dr M Hamaguchi (Nagoya University School of Medicine). DN c-Src expression vector was from Dr CSS Wong (Hong Kong University, Hong Kong, China). H-Ras (V12G)-NIH3T3 was derived from Dr K Furukawa (Nagoya University School of Medicine). Mock-NIH3T3 cells were prepared by transfecting pcDNA3.1 to NIH3T3. Constitutive active Stat3 expression vector was from Dr A Iwama (Chiba University, Chiba, Japan). JNK1 expression vector was the gift of Dr A Atfi (INSERM U482, Hospital Saint-Antoine, Paris, France). Constitutive active PKCa expression vector was from Dr Jae-Won Soh (Inha University, Inchon, Korea).
AUF1 expression vector was from Dr Y Arao (National Institute of Environmental Health Sciences, USA). HuR expression vector was the generous gift of Dr J Hauber (Heinrich-Pette Institut, Hamburg, Germany). siRNAs for AUF1, HuR and mouse SPHK1 were purchased from Sigma Genosys (Hokkaido, Japan). Their sequences were described in the Supplementary information.
Go6976, calphostin C, rottlerin, cell-permeable Stat3 inhibitor and JNK1 inhibitor (SP600125) were from Calbiochem (La Jolla, CA, USA).
Viable cell counting
Viable cells were measured in triplicate by trypan blue dye exclusion. The effect of siRNA of SPHK1 on cell proliferation was examined 2 days after transfecting either siRNA of SPHK1 or scramble siRNA to NIH3T3.
SPHK enzyme activity SPHK enzyme activity was measured as described previously (Sobue et al., 2005) . Our assay mainly detected SPHK1 but not SPHK2 enzyme activity because of the presence of 0.25% Triton X-100 and the absence of 1 M KCl in the reaction mixture (Liu et al., 2000) .
Western blotting
Western blotting using antimouse SPHK1 antibody was performed as described previously (Sobue et al., 2005) . Other antibodies used were as follows: anti-Src antibody and anti-AUF1 antibody (Upstate Biotechnology, Lake Placid, NY, USA), anti-phospho-Src family (Tyr416) antibody (Cell Signaling Technology, Danvers, MA, USA), anti-b-actin antibody (Cytoskeleton Inc., Denver, CO, USA), anti-ERK, anti-p-ERK, anti-AKT, anti-p-AKT, anti-p38, anti-p-p38, anti-Stat3, anti-p-Stat3, anti-JNK1, anti-p-JNK1, anti-PKCa, anti-p-PKCs and anti-HuR antibody (Santa Cruz Biotechnology Inc., Santa Cruz, CA, USA), antiphosphotyrosine antibody (Calbiochem, San Diego, CA, USA), antiphosphoserine/threonine antibody (Upstate Biotechnology) and antiserine-phosphorylated PKC substrate antibody (Cell Signaling Technology, Beverly, MA, USA).
Quantitative and semiquantitative RT-PCR
Real-time quantitative RT-PCR was performed according to the method described previously (Sobue et al., 2006) with minor modifications. SPHK1 mRNA was calculated as the ratio of SPHK1 mRNA to b-actin mRNA. For the nuclear run-on assay of mSPHK1, semiquantitative RT-PCR method was used according to Sobue et al. (2005) . Further information was provided as Supplementary information. 0 UTR of sphingosine kinase 1 (SPHK1). In mock-NIH3T3, SPHK1 mRNA degradation occurred, as the AUF1 level was higher than that of v-Src-NIH3T3. In contrast, decrease in AUF1, tyrosine phosphorylation of AUF1 and increase in serine-phosphorylated HuR may promote the stabilization of the SPHK1 mRNA in v-Src-NIH3T3. promoter of mSPHK1a were used as shown in Figure 3c . Reporter construct (5 mg) and b-gal expression vector (1 mg) were co-transfected to either mock-NIH3T3 or v-Src-NIH3T3 by the calcium precipitation method. Relative promoter activity was expressed as luciferase activity/b-gal. The value of luc-4/pGL3 in mock-and v-Src-NIH3T3 was determined as 1.0, respectively.
Nuclear run-on assay
The rate of mature SPHK1 transcription was determined by the nuclear run-on assay as described previously (Patrone et al., 2000) . Harvested cells were resuspended in 4 ml of Nonidet P-40 (NP-40) lysis buffer containing 10 mM Tris-HCl (pH 7.4), 10 mM NaCl, 3 mM MgCl 2 and 0.5% NP-40 for 5 min at 4 1C. After collecting nuclei, they were resuspended in 100 ml of glycerol buffer containing 50 mM Tris-HCl (pH 8.3), 40% glycerol, 5 mM MgCl 2 and 0.1 mM EDTA. They were stored at À30 1C until use. Nuclear run-on and RNA isolation were performed in the presence of biotin-16-UTP (Roche, Mannheim, Germany). Dynabeads M-280 (Dynal Biotech, Oslo, Norway), which were used to capture the biotin-labeled molecules from the purified nuclear RNA, were washed once with 15% formamide and twice with 2 Â SSC and resuspended in 8.5 ml of diethylpyrocarbonate-treated H 2 O before preparing cDNA using random hexamer. Semiquantitative RT-PCR was then performed as described in the previous RT-PCR section.
mRNA half-life The half-life of mRNA was measured according to Fritz et al. (1995) and Leclerc et al. (2002) . Briefly, logarithmically growing cells were treated with 5 mg/ml actinomycin D. After an indicated incubation period (15-120 min), total RNA was isolated for quantitative RT-PCR as described in the previous section. The relative mRNA level of SPHK1 (SPHK1/b-actin) before actinomycin D treatment was defined as 100%, and the half-life of SPHK1 mRNA was calculated. Effects of 3 0 -and 5 0 -untranslated region (3 0 UTR and 5 0 UTR) of mouse SPHK1 on its mRNA half-life. To analyse the involvement of 3 0 UTR of mouse SPHK1 in its mRNA decay, 3 0 UTR of mouse SPHK1 was cloned. Description of cloning was provided as Supplementary information. pGL3 promoter vectors containing 283 bp (full length) 3 0 UTR, 138 bp (the first half) 3 0 UTR and 145 bp (the second half) 3 0 UTR were used for experiments. A total of 0.5 mg of this vector and 0.2 mg of the b-gal expression vector were transfected into v-Src-or mock-NIH3T3 cells. Similarly, 5 0 UTR of mSPHK1a was also cloned as described in Supplementary information. The corrected luciferase activity (Luc/ b-gal) was calculated as the parameter of SPHK1 mRNA decay.
Modulation of AUF1 and HuR gene expression
Overexpression of AUF1 in v-Src-NIH3T3 was performed using FuGENE6 (Roche). siRNAs of AUF1, HuR as well as scramble siRNA were transfected using FuGENE6 according to the recommendation of the manufacturer.
RNA-chromatin immunoprecipitation assay
An RNA-ChIP assay was performed according to Pan et al. (2005) . Briefly, cultured cells were treated with 1% formaldehyde at 37 1C for 15 min, and lysed with nuclei-swelling buffer. After sonication and centrifugation, cytoplasmic extract was incubated at 4 1C overnight with 5 mg of either anti-AUF1, anti-HuR or nonspecific control antibody. Cytoplasmic extract not incubated with antibody was saved as an input sample. The antibody-bound complex was precipitated by protein A-Sepharose beads (Amersham Biosciences, Little Chalfont, Buckinghamshire, UK). The beads were washed and the protein-RNA complex was eluted from the protein A-Sepharose beads with 250 ml of elution buffer (1% SDS and 0.1 M NaHCO 3 ) at 37 1C for 15 min. The RNA in the immunoprecipitated complex and the RNA in the previously saved input fraction were released by reversing the crosslinking at 65 1C for 2 h with 200 nM NaCl and 20 mg of proteinase K. RNA was then extracted from the solution and subjected to RT-PCR using primers to amplify a sequence in the 3 0 UTR of SPHK1 (upper 5 0 -CTCTGTGCCTTTGTCTACTCT-3 0 ; lower 5 0 -TGGAAAAGTCTCTTTATTTGA-3 0 ). The PCR conditions were 96 1C for 15 s, 54 1C for 30 s and 72 1C for 30 s, and 40 cycles.
Biotinylated RNA pull-down assay In vitro transcription of the full-length 3 0 UTR of SPHK1 was described in the Supplementary information. We also prepared the eight 3 0 -UTR fragments (Thermo Fisher Scientific, Ulm, Germany) with a biotin attached to the 3 0 -terminus. Cytoplasmic proteins were extracted with Nuclear and Cytoplasmic Extraction Reagents (PIERCE, Rockford, IL, USA). Reaction mixture containing 1 Â binding buffer (20 mM HEPES, pH 7.8, 50 mM KCl, 3 mM MgCl 2 , 0.5 mM EDTA, 0.05% Triton X-100, 0.5 mM dithiothreitol), 80 mg tRNA, 1% bovine serum albumin, RNase inhibitor and biotinylated RNA (2-15 mg) were incubated at 4 1C for 30 min. Following the incubation, cytoplasmic proteins (15-100 mg) were added and incubated at 4 1C for 30 min. Ribonucleoprotein complexes were isolated using streptavidin-conjugated Dynabeads (Dynal Biotech). The presence of HuR/AUF1 in ribonucleoprotein complex was identified by western blot analysis with either an anti-HuR or anti-AUF1 antibody.
Statistical analysis
Results were expressed as mean ± s.d. Statistical analysis was performed using Student's t-test and analysis of variance for significance. P-values o0.01 were considered significant.
